RIL
ARQT icon

Rothschild Investment LLC’s Arcutis Biotherapeutics ARQT Stock Holding History

Rothschild Investment LLC’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3K Buy
565
+36
+7% +$919 ﹤0.01% 1579
2025
Q4 		$15.4K Buy
529
+34
+7% +$870 ﹤0.01% 1416
2025
Q3 		$9.33K Buy
495
+255
+106% +$4.02K ﹤0.01% 1469
2025
Q2 		$3.37K Sell
240
-40
-14% -$561 ﹤0.01% 1712
2025
Q1 		$4.38K Buy
280
+140
+100% +$1.97K ﹤0.01% 1502
2024
Q4 		$1.95K Buy
140
+5
+4% +$55 ﹤0.01% 1817
2024
Q3 		$1.26K Buy
135
+75
+125% +$740 ﹤0.01% 1997
2024
Q2 		$558 Buy
60
+45
+300% +$407 ﹤0.01% 1943
2024
Q1 		$149 Buy
+15
New +$112 ﹤0.01% 1911

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return